Abstract  Dyslipidemia is an important risk factor for cardiovascular disease (CVD) and atherosclerosis. When dyslipidemia coincides with other metabolic disorders such as obesity, hypertension, and glucose intolerance, defined as the metabolic syndrome (MS), individuals present an elevated risk to develop type 2 diabetes (T2D) as well as CVD. Because the MS epidemic represents a growing public health problem worldwide, the development of therapies remains a major challenge. Alterations of bile acid pool regulation in T2D have revealed a link between bile acid and metabolic homeostasis. The bile acid receptors farnesoid X receptor (FXR) and TGR5 both regulate lipid, glucose, and energy metabolism, rendering them potential pharmacological targets for MS therapy. This review discusses the mechanisms of metabolic regulation by FXR and TGR5 and the utility relevance of natural and synthetic modulators of FXR and TGR5 activity, including bile acid sequestrants, in the treatment of the MS.—Porez, G., J. Prawitt, B. Gross, and B. Staels. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 2012. 53: 1723–1737.

Supplementary key words  atherosclerosis • FXR • glucose metabolism • lipid metabolism • TGR5

Dyslipidemia is a major risk factor for cardiovascular disease (CVD). The deposition of plasma lipids in the arterial intima induces a local inflammatory response and extensive vascular remodeling, resulting in the formation of atherosclerotic plaques (1). Plaque rupture or erosion causes myocardial infarction or stroke. The prevalence of dyslipidemia, characterized by elevated plasma triglycerides (TGs) and low HDL-cholesterol (HDL-C), in combination with obesity, elevated blood glucose levels, and/or hypertension termed the metabolic syndrome (MS), increases worldwide, mainly due to a sedentary lifestyle (increased caloric intake, decreased exercise). In addition to a higher incidence of CVD, individuals with the MS are at a higher risk to develop type 2 diabetes (T2D), which further increases the risk for CVD, the most common cause of death from T2D (http://www.who.int/mediacentre/factsheets/fs312/en/index.html). Obesity and T2D are associated with nonalcoholic fatty liver disease (NAFLD), a pathological accumulation of lipids in the liver (steatosis), which, associated with inflammation, evolves into nonalcoholic steatohepatitis (NASH). NASH may cause cirrhosis and cancer, and in the case of complete liver failure, transplantation is the only option (2). Therefore, an appropriate management of the MS is essential to prevent these associated metabolic disorders. The most efficacious treatment consists of lifestyle changes, which is, however, often difficult to implement due to a lack of patient

This work was supported by grants from the Agence Nationale de la Recherche (ANR), INSERM, Région Nord-Pas-De-Calais, Contrats de Projets Etat Région (CPER), and LABEX EGID. G.P. is financed by the INSERM and the Région Nord-Pas-De-Calais, and J.P. by the CPER "Cell-specific regulation of atherosclerosis and vascular function by the nuclear receptor FXR." B.S. is a member of the Institut Universitaire de France.

Manuscript received 27 January 2012 and in revised form 6 March 2012.
Published, JLR Papers in Press, May 1, 2012
DOI 10.1194/jlr.R024794

Copyright © 2012 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org

Bile acids are amphipathic molecules and major constituents of bile. Their synthesis from cholesterol in the hepatocyte represents an important way to eliminate cholesterol from the human body. Stored in the gallbladder, bile is secreted into the intestine after a meal, where they facilitate the absorption of lipid nutrients and lipid-soluble vitamins. Of the bile pool, 95% is reabsorbed in the ileum and returns to the liver, a pathway known as the enterohepatic cycle. The remaining 5% of the bile pool is lost with the feces and replaced by hepatic de novo synthesis.

The synthesis of bile involves two distinct pathways: the classic and the alternative pathway with cholesterol-7α-hydroxylase (CYP7A1) and sterol-27-hydroxylase (CYP27A1), respectively, as key enzymes (5). In a first step, 7α-hydroxycholesterol is formed from cholesterol by microsomal CYP7A1, which is then converted into the primary bile acid chenodeoxycholic acid (CDCA) and cholic acid (CA) by the action of several enzymes, including sterol-12α-hydroxylase (CYP8B1), 25-hydroxycholesterol-7α-hydroxylase (CYP7B1), and CYP27A1 (6). CYP8B1 is the rate-limiting enzyme in the synthesis of CA, determining the CA/CDCA ratio in humans and CA/muricholic acid (MCA) ratio in mice. Primary BA are finally conjugated to glycine (humans) or taurine (mice) by BA-CoA synthetase (BACS) and BA-CoA amino acid N-acyltransferase (BAT) (7, 8). Once excreted into the small intestine, primary BA are deconjugated and partially converted into secondary BA by dehydroxylation (9).

These modifications are catalyzed by enzymes of the microbial flora, which in turn are regulated by BA (10). In humans, the most abundant secondary BA are lithocholic acid (LCA) and deoxycholic acid (DCA) (9, 11). Hydrophobicity of these BA is increased, facilitating their absorption by the colon epithelium. The BA pool of mice and humans is different. In mice, CDCA is quantitatively converted into MCA, rendering the pool more hydrophilic than in humans.

BA, which at high concentrations are toxic detergents, regulate their own metabolism. In addition to inhibiting the expression of their transepithelial transporters apical sodium/bile acid cotransporter (ASBT) and organic solute transporter (OST)α/β in the intestine (12), they are strong transcriptional inhibitors of CYP7A1, exerting a negative feedback regulation of their own synthesis (6). These regulatory functions of BA are mediated by signaling through their receptors, particularly FXR.

**Bile acid receptors**

The best-studied BA receptors are the nuclear receptor FXR and the membrane receptor TGR5 (13). Noteworthy, BA can also activate other nuclear receptors, such as the human steroid and xenobiotic receptor (SXR) and its rodent homolog pregnane X receptor (PXR), vitamin D receptor (VDR), and constitutive androstane receptor (CAR) (14, 15). These receptors are also implicated in lipid and glucose metabolism, but their activation seems to occur at nonphysiological BA concentrations. Thus, we focus on FXR- and TGR5-mediated functions of BA in this review (Fig. 1).

FXR is expressed in several tissues, such as liver, intestine, adipose tissue, the vascular wall, pancreas, and kidney (16). When FXR is activated by a ligand, it binds to FXR response elements (FXRE) in the promoter of its target genes, either as a monomer or as a heterodimer with the retinoid X receptor (RXR), regulating their transcription. FXR can also indirectly regulate gene expression notably via the induction of other transcription factors like the small heterodimer partner (SHP). Thus, in the liver, FXR-activated SHP inhibits the liver receptor homolog (LRH)-1, liver X receptor (LXR), and hepatocyte nuclear factor (HNF)-4α, all necessary for optimal CYP7A1 transcription (17–19). BA further induce an intestinal-hepatic signaling axis by activating FXR in the intestine, which enhances the transcription of fibroblast growth factor (FGF)19 in humans and FGF15 in mice. FGF19/15 is secreted into the circulation and activates the FGF receptor (FGFR)4 on hepatocytes, leading to the repression of CYP7A1 expression via the activation of the c-jun N-terminal kinase (JNK) (20, 21). The transport of BA across the ileal epithelium by ASBT and OSTα/β is rate limiting for the activation of hepatic as well as intestinal FXR signaling. FXR exerts a negative feedback loop by inhibiting the expression of both transporters (12). Furthermore, FXR is subject to posttranscriptional modifications, such as phosphorylation or acetylation, which regulate its activity (22, 23).

TGR5 is a member of the rhodopsin-like superfamily of G protein-coupled receptors, with most important expression
levels in gallbladder, ileum, and colon (24). Primary and secondary BA activate TGR5 (13, 24, 25). TGR5 activation leads to receptor internalization and liberation of the Gas subunit, which activates adenylate cyclase, subsequently inducing cAMP production and protein kinase A (PKA) activation. PKA phosphorylates the cAMP-response element-binding protein (CREB) and induces the transcription of its target genes (13, 26).

FUNCTIONS OF BILE ACID RECEPTORS

FXR and lipid metabolism

The FXR-mediated regulation of BA synthesis, which represents a major pathway of cholesterol catabolism, suggests an implication of FXR in the control of lipid metabolism. Indeed, mice deficient for FXR are dyslipidemic, with elevated plasma TG and HDL-C as well as non-HDL-C levels (27–29).

The increase of non-HDL-C in FXR-deficient mice occurs both in the VLDL and LDL lipoprotein fraction, illustrated by an elevation of plasma apoB concentrations (27, 28). Hepatic LDL receptor (LDLR) expression is not different, but the production of TG-rich, apoB-containing lipoproteins as well as intestinal cholesterol absorption are increased, probably causing the elevated non-HDL-C levels upon FXR deficiency (27). In the same line, FXR activation in mice with a synthetic FXR agonist reduces intestinal cholesterol absorption by 50% (30). The authors propose a reduction in BA pool size and hydrophobicity index (due to an increased tauro-β-MCA/TCA ratio) upon FXR activation (31) as underlying mechanism, as a reduced BA pool hydrophobicity has been associated with a decrease in cholesterol absorption (32).

Fig. 1. Functions of FXR and TGR5 in metabolic homeostasis and effect of bile acid receptor modulation. See text for details. The indication of agonist or BAS effects was omitted in case of contradictory data in the literature. Functions of FXR, black on white; functions of TGR5, white on black; functions of both receptors, white on gray. Blue flash, effect of receptor activation; red flash, effect of bile acid sequestration. SM, skeletal muscle; WAT, white adipose tissue.
kexin type (PCSK)\textsubscript{9}, a LDLR inhibitor (35). Both effects suggest that FXR activation could lower plasma LDL-cholesterol (LDL-C) in vivo. However, CDCA treatment in humans has no effect or even increases LDL-C (36, 37), possibly due to the FXR-dependent inhibition of CYP7A1 resulting in a decreased demand in cholesterol for BA synthesis and a decreased LDL uptake. In the same line, BAS, which deactivates FXR by limiting the availability of endogenous ligands, lowers LDL-C (3, 38). Due to the increase in BA synthesis, endoplasmatic reticulum cholesterol is depleted, thus activating the sterol regulatory element binding protein (SREBP)\textsubscript{2}, which in turn upregulates LDLR expression (38, 39).

Recently, it has been shown that CA represses human LPA gene expression in transgenic mice in a FXR-dependent manner. The corresponding protein, apo(a), covalently binds to apoB forming lipoprotein(a) [Lp(a)], a plasma lipoprotein strongly associated with a high risk for the development of atherothrombotic diseases (40). Further, in patients with biliary obstruction and thus elevated plasma BA levels, plasma Lp(a) concentrations are very low but return to normal levels after successful removal of the obstruction (40). Thus, regarding the management of Lp(a) levels and the associated atherosclerosis risk, FXR activation, which may exert positive effects on proatherogenic apoB-containing lipoproteins, appears to be indicated.

The elevation of HDL-C observed in FXR-deficient mice is associated with the presence of larger HDL particles and a reduced uptake of HDL-C esters by the liver due to a decreased expression of the HDL receptor scavenger receptor class B member (SR-B)\textsubscript{1} (27, 30). Accordingly, the administration of an FXR ligand decreases HDL-C levels, which is associated with an increase of hepatic SR-B1 expression and of hepatic cholesterol clearance (30). HDL-C modulation by FXR is apoAI-independent, as apoAI expression is not altered in liver or ileum of FXR-deficient mice (27) or upon FXR activation (30). FXR further induces the expression of the phospholipid transfer protein (PLTP) (41), which contributes to HDL remodeling (42). These data suggest that FXR activation in mice promotes reverse cholesterol transport, however, reflected by a decrease in HDL-C.

Overall, in both mice and humans, FXR activation improves hepatic steatosis and decreases steatosis. Thus, FXR activation might be useful to improve hepatic steatosis and even NASH.

**FXR and atherosclerosis**

Loss of FXR function in mouse models of atherosclerosis has produced contradictory results, depending on the animal model and gender. On the one hand, the absence of FXR in apoE-deficient mice fed an atherogenic diet leads to more severe atherosclerosis with a decreased survival rate (60). On the other hand, FXR deficiency in LDLR-deficient mice is atheroprotective (61, 62). The effect of FXR activation on decreasing atherosclerotic plaque burden seems in part due to an improvement of the lipid profile (63–65).

In addition to controlling metabolic risk factors of atherosclerosis, FXR is expressed in different cell types of the
blood vessel, including vascular smooth muscle cells (VSMC) of coronary arteries and the aorta (66). FXR activation enhances apoptosis (66) and inhibits inflammation and migration (67) of rat VSMC, effects that may attenuate vascular remodeling and atherosclerosis development. Further, FXR directly promotes the transcription of angiotensin type 2 receptor (AT2R) (68), which prevents neointimal formation in balloon-injured rat carotid arteries (69) and participates in the hypotensive effects of angiotensin type 1 receptor (AT1R) blockers (70) and the cardioprotective effects of peroxisome proliferator activated receptor (PPAR)γ ligands (71).

FXR is also expressed in endothelial cells (72). FXR activation regulates the vascular tone by increasing endothelial nitric oxide synthase (eNOS) expression and production of the vasodilator nitrogen oxide (NO), while decreasing expression of the vasoconstrictor endothelin (ET)-1 (72–74). Furthermore, FXR stimulates the catabolism of circulating asymmetric dimethylarginine (ADMA), an endogenous NO synthase inhibitor (75, 76). Thus, FXR exerts vasodilator effects. However, impairment of endothelium-dependent relaxation due to decreased sensitivity of VSMC to NO has been reported after chronic FXR stimulation in cultured rabbit arteries (77).

Overall, FXR activation appears to protect against atherosclerotic plaque formation.

**FXR and glucose metabolism**

The expression of both FXR and CYP7A1 is increased by glucose and decreased by insulin (78), indicating a link between BA and glucose metabolism. Indeed, FXR modulates glucose homeostasis. The gluconeogenic genes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase), have been shown to be regulated by FXR, however, with discordant results in the literature (79, 80). FXR activation increases PEPCK expression and glucose output in primary rat hepatocytes (80). In contrast, CA treatment decreases the expression of multiple gluconeogenic genes, including PPARγ coactivator (PGC)-1α, PEPCK, and G6Pase, and decreases fasting blood glucose levels in wild-type mice, but not in FXR- or SHP-deficient mice, indicating a FXR-SHP axis dependency (81). In addition, CDC2 increases PEPCK expression by decreasing HNF4α activity in a FXR-independent manner (82, 83). Further, FXR-deficient mice reveal an accelerated induction of glycolytic and lipogenic genes upon high-carbohydrate refeeding, whereas FXR activation decreases the induction of glucose-responsive genes (79). FXR-deficient mice have less hepatic glycogen (78), and conversely, FXR activation leads to an increase of glycogen synthesis (57). Moreover, FXR deficiency is associated with a delayed intestinal glucose absorption due to an enhanced glucose phosphorylation cycle in proximal enterocytes (84), another action site of FXR in the regulation of glucose metabolism.

Three groups have shown independently that FXR-deficient mice display peripheral insulin resistance (29, 57, 81). FXR plays a role in maintaining adipocyte differentiation and function (29, 85, 86), which might explain why the absence of FXR affects peripheral insulin sensitivity (29). Glucose-stimulated insulin secretion by pancreatic islets is impaired in FXR-deficient mice (87). Furthermore, FXR increases the expression of insulin in a glucose-dependent manner via the induction of the transcription factor KLF11 (88). In addition, FXR increases insulin secretion by enhancing GLUT2 translocation to the plasma membrane by a nongenomic effect via Akt phosphorylation (88). The effects of synthetic FXR agonists on glucose homeostasis are less clear. Two studies have reported that activation of FXR in db/db or ob/ob mice decreases gluconeogenic gene expression and improves hyperglycemia and peripheral insulin resistance (29, 57). In contrast, a recent third paper shows that FXR activation by the synthetic agonist GW4064 in mice with diet-induced obesity aggravates glucose intolerance by reducing the BA pool size. Consequently, the administration of BA restores the BA pool and reverses the GW4064-induced metabolic effects (89). In line with this concept, FXR deficiency has been shown to protect from genetic and diet-induced obesity (50, 90) and to improve glucose homeostasis by increasing peripheral glucose clearance and adipose tissue insulin sensitivity (50). The deletion of hepatic FXR has no protective effect (50), highlighting the importance of extra-hepatic FXR.

Even though partly controversial, these data provide evidence for a regulatory role of FXR in glucose metabolism and insulin sensitivity. FXR might exert differential effects in lean versus obese mice. Tissue-specific models might be necessary to dissect the complex effects of FXR on insulin resistance. From a pharmacological viewpoint, it is unclear whether inhibition or activation of FXR would be more efficient to correct altered glucose metabolism.

**TGR5 and energy metabolism**

Mice deficient for TGR5, the membrane receptor for BA, exhibit a decreased BA pool size even though fecal BA excretion is unaltered (91). In addition, they are protected from gallstone formation (92). TGR5 is expressed in human cholangiocytes (gallbladder epithelial cells) (93) and is involved in regulating bile composition by inducing chloride secretion by cholangiocytes (94). Treatment with the TGR5 agonist INT-777 stimulates gallbladder filling (95).

Interestingly, TGR5 also regulates metabolic homeostasis. Whereas TGR5-deficient mice have normal weight and fat mass (92), when fed a high-fat diet, females display increased weight gain resulting from increased fat accumulation (91). Conversely, TGR5 activation by supplementing CA to the diet prevents the high-fat-induced changes in adipose tissue mass and morphology (96). The role of TGR5 in weight loss has been associated with increased energy expenditure rather than decreased caloric intake (96). TGR5 activation induces deiodinase-2 expression in murine brown adipose tissue (BAT) and human skeletal muscle cells by increasing cAMP levels. Deiodinase-2-mediated conversion of inactive thyroxine (T4) to active 3,3',5'-tri-iodothyronine (T3) enhances the expression of uncoupling proteins (UCP), mitochondrial oxidative
phosphorylation and energy expenditure in BAT and skeletal muscle (96). Comparable results have been obtained with semisynthetic (INT-777) (96) and natural (oleanolic acid) (97) TGR5, but not with FXR agonists (98). Thus, TGR5 agonists might promote energy expenditure.

**TGR5 and lipid metabolism**

TGR5 also affects hepatic lipid content. Female TGR5-deficient mice present an increase in hepatic fat content, especially when fed a high-fat diet (92). In line, TGR5 activation with INT-777 improves liver function by decreasing steatosis and preventing fibrosis (98). Additionally, plasma TG and nonesterified fatty acid levels are decreased upon TGR5 activation (98). Thus, TGR5 activation might be useful for the treatment of NAFLD.

**TGR5 and atherosclerosis**

A recent study has reported antiatherosclerotic effects of TGR5 activation (99). The administration of INT-777 to LDLR-deficient mice attenuates atherosclerotic lesion size only in the presence of TGR5, due to a decrease in plaque macrophage content and intraplaque inflammation. This effect is attributed to TGR5-induced cAMP signaling in macrophages, causing the inhibition of nuclear factor κ light-chain enhancer of activated B cells (NF-κB) activity and the subsequent production of pro-inflammatory cytokines (99).

**TGR5 and glucose homeostasis**

In mice fed a high-fat diet, TGR5 activation lowers serum glucose and insulin levels and improves glucose tolerance (97, 98). TGR5-transgenic (TGR5-tg) mice also display improved diet-induced glucose intolerance without changes in body weight (98). TGR5 activation induces glucagon-like peptide (GLP)-1 production by enteroendocrine cells (100), hence enhancing postprandial insulin secretion (101). TGR5 induction of GLP-1 in STC-1 (enteroendocrine) cells is mediated by an increase in cAMP levels and cytochrome C oxidase (Cox) activity, leading to enhanced cellular oxygen consumption and rise in the ATP/ADP ratio. This signal induces the closing of KATP channels and the opening of calcium-gated voltage channels (CAs), triggering GLP-1 secretion (98). Furthermore, enhanced plasma GLP-1 in TGR5-tg mice fed a high-fat diet is associated with a normal pancreatic islet distribution and higher insulin content compared with hypertrophic islets with low insulin content in control mice fed a high-fat diet (96). In contrast, TGR5-deficient mice have impaired glucose tolerance, and INT-777 treatment has no effect on GLP-1 secretion in these mice (98). In humans, a genetic variation within the TGR5 gene is, however, not associated with the development of prediabetic phenotypes (102).

**MODULATORS OF BILE ACID RECEPTOR ACTIVITY AND THEIR CLINICAL APPLICATION**

As outlined above, FXR and TGR5 contribute to the regulation of a panel of pathways linking BA and metabolic homeostasis. As a result, both receptors are potential targets for the treatment of cholestasis, hyperlipidemia, NAFLD/NASH, CVD, and T2D. Consequently, an extensive effort has been put into the identification and development of modulators of FXR and TGR5 activity. In the following sections, we discuss the available compounds and the status of their (pre)clinical evaluation (Table 1 and Fig. 1).

**FXR agonists**

Endogenous primary (CDCA, CA) and secondary (LCA, DCA) BA activate FXR with different efficacy (CDCA > LCA = DCA > CA), with the conjugated forms being less potent (103, 104). Mainly CDCA and CA have been used to study FXR function in vitro and in vivo. However, their conversion into secondary BA species in vivo and the fact that their specificity is not restricted to FXR often complicates the interpretation of the results. Thus, all four BA also activate TGR5 and, with exception of CDCA, PXR (15, 26).

Before BA were known to activate FXR, CDCA was tested for the treatment of gallstones to enrich the bile and dissolve the stone. Four studies in small patient cohorts (n = 8–15) find a reduction in plasma TG (55, 56, 105, 106) but no change in total plasma cholesterol (55, 56, 106), and one reports decreased HDL-C levels (105). The only study conducted in a large number of patients (n = 916) observes an increase of LDL-C upon CDCA administration (36). Thus, even though CDCA treatment lowers elevated plasma TG levels, the impact on cholesterol metabolism is not conclusive and might be unfavorable. In addition, elevated liver enzymes and diarrhea might occur as side effects (36, 56), discouraging the use of CDCA in the clinic. Nevertheless, a study has recently been launched in patients with MS and dyslipidemia (scheduled n = 48) to test the effect of CDCA on plasma TG levels, defined as primary endpoint, hepatic fat content to be determined by nuclear magnetic resonance and hepatic glucose metabolism to be measured by hyperinsulinemic euglycemic clamp analysis (http://clinicaltrials.gov; NCT00465751).

A procyanidin extract from grape seeds reduces postprandial plasma TG levels in wild-type but not in FXR- or SHP-deficient mice, decreases the expression of lipogenic genes, such as SREPB1c, and enhances the transcriptional activity of FXR, although only in the presence of CDCA (107, 108). However, it is unknown which component of the extract exerts these effects. Further, cafestol, a diterpene present in unfiltered coffee, activates FXR as well as PXR. Cafestol treatment of APOE3-Leiden mice increases total plasma cholesterol and consistently represses CYP7A1 and CYP8B1 expression in wild-type mice but not in FXR-deficient mice (109).

The most clinically advanced FXR agonist is the semisynthetic compound INT-747 (6-ethyl-CDCA or obeticholic acid), which was designed based on the structure of CDCA and is 10 times more potent (110). Results from in vitro and in vivo studies indicate that INT-747 exerts a hepatoprotective effect in acute LCA-induced necrosis (110), fibrosis (111), and cholestasis (112), and it further protects...
TABLE 1. Modulators of BA receptor activity and BA metabolism

<table>
<thead>
<tr>
<th>Compound</th>
<th>Chemical class (Alternative name)</th>
<th>EC50 (µM)</th>
<th>Provider</th>
<th>Clinical development phase</th>
<th>Biological effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FXR agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural DCA</td>
<td>Endogenous bile acids</td>
<td>10 - 20</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase II, phase III for PBC planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(96, 103-106)</td>
</tr>
<tr>
<td>LCA</td>
<td>3.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA</td>
<td>&gt;1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholic acid extract</td>
<td>Fraxinol from grape seed</td>
<td>Preclinical</td>
<td></td>
<td>Drug treatment of cholestasis</td>
<td>(107, 108)</td>
<td></td>
</tr>
<tr>
<td>Caerulein</td>
<td>Diacereine from unfilitered coffee</td>
<td>Preclinical</td>
<td></td>
<td>Drug treatment of cholestasis</td>
<td>(109)</td>
<td></td>
</tr>
<tr>
<td>Synthetic INT-747</td>
<td>O-butyrate-CICA (Obeticholic acid)</td>
<td>0.1</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase II, phase III for PBC planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(110)</td>
</tr>
<tr>
<td>GW-4064</td>
<td>Inosazole</td>
<td>0.065</td>
<td>GlassSmithKline</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis</td>
<td>(110a)</td>
</tr>
<tr>
<td>GSK2334</td>
<td>GW4064 analog (Qinotin)</td>
<td>0.05</td>
<td>GlassSmithKline</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis</td>
<td>(110b)</td>
</tr>
<tr>
<td>Compound 13</td>
<td>GW4064 analogs</td>
<td>3.0</td>
<td>Phenex</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis</td>
<td>(110c)</td>
</tr>
<tr>
<td>Pn-102</td>
<td>Non-steroidal</td>
<td>Phenex</td>
<td>Phase I, phase II for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(110d)</td>
<td></td>
</tr>
<tr>
<td>FXR-450</td>
<td>Tetrahydrozepino indole (WRT-324545)</td>
<td>0.016</td>
<td>Wyeth (Pizer)</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(110e)</td>
</tr>
<tr>
<td>4cc</td>
<td>FXR-450 analog</td>
<td>0.052</td>
<td>Wyeth (Pizer)</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(110f)</td>
</tr>
<tr>
<td>Farnesylase</td>
<td>Farnesylase inhibitor</td>
<td>0.025</td>
<td>Phenex</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis</td>
<td>(110g)</td>
</tr>
<tr>
<td><strong>FXR antagonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural Guggulsterone</td>
<td>Part of guggulipid, plant seed from the guggul tree</td>
<td>Approved in India</td>
<td></td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(125-127, 129, 130)</td>
<td></td>
</tr>
<tr>
<td><strong>TGR5 agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural DLCA</td>
<td>Endogenous bile acids</td>
<td>0.58</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase II, phase III for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(131)</td>
</tr>
<tr>
<td>DCA</td>
<td>1.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CA</td>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obecacetate</td>
<td>Obecacetate</td>
<td>13.6</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase I, phase II for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(132)</td>
</tr>
<tr>
<td>Farnesylase</td>
<td>Farnesylase inhibitor</td>
<td>2.25</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase I, phase II for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(133)</td>
</tr>
<tr>
<td><strong>TGR5 antagonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural DCA</td>
<td>Endogenous bile acids</td>
<td>0.58</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase II, phase III for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(134)</td>
</tr>
<tr>
<td>Pn-102</td>
<td>Non-steroidal</td>
<td>Phenex</td>
<td>Phase I, phase II for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(135)</td>
<td></td>
</tr>
<tr>
<td>FXR-450</td>
<td>Tetrahydrozepino indole (WRT-324545)</td>
<td>0.016</td>
<td>Wyeth (Pizer)</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(136)</td>
</tr>
<tr>
<td>4cc</td>
<td>FXR-450 analog</td>
<td>0.052</td>
<td>Wyeth (Pizer)</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(137)</td>
</tr>
<tr>
<td>Farnesylase</td>
<td>Farnesylase inhibitor</td>
<td>0.025</td>
<td>Phenex</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(138)</td>
</tr>
<tr>
<td><strong>TGR5 dual agonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural DCA</td>
<td>Endogenous bile acids</td>
<td>0.58</td>
<td>Intercept Pharmaceuticals</td>
<td>Phase II, phase III for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(139)</td>
</tr>
<tr>
<td>Pn-102</td>
<td>Non-steroidal</td>
<td>Phenex</td>
<td>Phase I, phase II for MS / NASH planned</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(140)</td>
<td></td>
</tr>
<tr>
<td>FXR-450</td>
<td>Tetrahydrozepino indole (WRT-324545)</td>
<td>0.016</td>
<td>Wyeth (Pizer)</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(141)</td>
</tr>
<tr>
<td>4cc</td>
<td>FXR-450 analog</td>
<td>0.052</td>
<td>Wyeth (Pizer)</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(142)</td>
</tr>
<tr>
<td>Farnesylase</td>
<td>Farnesylase inhibitor</td>
<td>0.025</td>
<td>Phenex</td>
<td>Preclinical</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(143)</td>
</tr>
<tr>
<td><strong>BA sequestrants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colleselenum</td>
<td>Polymeric (Cholesterol-5-ol) (Waxall)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(144, 145, 153, 165)</td>
<td></td>
</tr>
<tr>
<td>Colestipol</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(146, 147, 151, 152, 162)</td>
<td></td>
</tr>
<tr>
<td>Colestipol</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(148, 149, 153, 165)</td>
<td></td>
</tr>
<tr>
<td>Colesaneously</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(144, 145, 146, 154, 165)</td>
<td></td>
</tr>
<tr>
<td>Colesaneously</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(147, 148, 151, 152, 162)</td>
<td></td>
</tr>
<tr>
<td>Cholestyramine</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(149, 150, 151, 165)</td>
<td></td>
</tr>
<tr>
<td>Colesevelam</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(151, 152, 162)</td>
<td></td>
</tr>
<tr>
<td>Colesevelam</td>
<td>Polymeric (Cholesterol-5-ol)</td>
<td>Daechi Samkyo</td>
<td>Approved for dyslipidemia and diabetes</td>
<td>Drug treatment of cholestasis; type 2 diabetes</td>
<td>(152, 153, 165)</td>
<td></td>
</tr>
</tbody>
</table>

DI, diet-induced; DIO, diet-induced obesity; GIP, gastric inhibitory protein; MCD, methionine-choline-deficient; OGTT, oral glucose tolerance test; STZ, streptozotocin; TG, total cholesterol.
from insulin resistance and hepatic steatosis in genetically obese rats (113).

A phase II study has confirmed the hepatoprotective effect of INT-747 in primary biliary cirrhosis (PBC), an autoimmune disease in which progressive destruction of the small bile ducts causes cholestasis, fibrosis, and cirrhosis. INT-747 treatment at doses of 10 mg and 50 mg daily for 12 weeks decreases plasma levels of alkaline phosphatase, a diagnostic parameter of PBC, alanine aminotransferase (ALT), and γ-glutamyl transferase (GGT), as well as the inflammatory markers C reactive protein (CRP) and immunoglobulin M ( Intercept Pharmaceuticals press release 31/03/2011, communication at the European Association for the Study of the Liver 2010). Curiously, the lower dose appears more effective. Half of the patients show pruritus (itching) as side effect. Subsequently, a phase III PBC program is planned ( Intercept Pharmaceuticals press release 31/03/2011). A second phase II study has evaluated the effect of INT-747 (25 mg and 50 mg daily for 6 weeks) in T2D patients with NAFLD. INT-747 treatment results in a small (1–2%) but significant weight loss and an improved insulin sensitivity (10–18% increase of the glucose disposal rate in hyperinsulinemic euglycemic clamps). Further, plasma ALT and GGT, as well as plasma TG levels, decrease. However, HDL-C levels decrease whereas LDL-C levels increase ( Intercept Pharmaceuticals press release 01/10/2009; communication at the European Association for the Study of Diabetes 2009), confirming that FXR activation may be beneficial to lower plasma TG but not cholesterol, similar to CDCA (36, 105). A third phase II study (“FLINT”, http://clinicaltrials.gov; NCT01265498) run by the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is currently ongoing, testing by pharmacokinetics in healthy Japanese men (http://clinicaltrials.gov; NCT00509756) and in healthy men and women in the US (http://clinicaltrials.gov; NCT00499629), but the results have not been reported.

A third class of synthetic, nonsteroidal FXR agonists is represented by fexaramine (121). Surprisingly, different gene profiles are induced by fexaramine, CDCA, or GW4064 in mouse hepatocytes (122). The conformation of the FXR-450 analog 14cc further decreases plasma TG, VLDL, and LDL-C in normolipemic rhesus monkeys, associated with reduced CYP7A1 and increases LDLr mRNA expression (120). FXR-450 has entered phase I studies in 2007 to analyze safety, tolerability, and pharmacokinetics in healthy Japanese men (http://clinicaltrials.gov; NCT00509756) and in healthy men and women in the US (http://clinicaltrials.gov; NCT00499629), but the results have not been reported.

Natural (steroidal) FXR ligands enter the enterohepatic cycle and may be metabolized to secondary BA in an uncontrollable manner, thus raising the interest in nonsteroidal compounds devoid of such metabolism. The first synthetic, nonsteroidal FXR agonist GW4064, was identified by screening a stilbene carboxylic acid library (114). GW4064 has been extensively used to study FXR functions in vitro and in vivo (e.g., it is reported to protect against cholesterol gallstones in mice (115), lower plasma TG and cholesterol, and to improve insulin resistance in genetic mouse models of obesity (29, 49, 57)). However, GW4064 presents some major pharmacodynamic limitations: a certain toxicity due to the stilbene moiety, a poor bioavailability, and the difficulty to target extrahepatic tissues due to fast metabolism by the liver. Thus, quite an effort has been made to develop GW4064 analogs with comparable potency and improved biological compatibility (116, 117); however, none has yet passed preclinical testing. In addition, a number of GW4064 analogs are handled by BA transporters and conjugated like BA, leading to very low plasma levels and hepatic accumulation (118).

The synthetic, nonsteroidal compound Px-102 has entered phase I to test tolerance and pharmacokinetic properties in men. A subsequent phase II study is planned in patients with MS and NAFLD to test whether Px-102 improves hypertriglyceridemia, insulin resistance, and NASH. The lipid-lowering effect of Px-102 in animals seems to be due to a reduction in intestinal uptake and an increase in excretion of neutral lipids and cholesterol (Phenex Pharmaceuticals AG press release 15/09/2011).

A chemical class of synthetic, nonsteroidal FXR agonists, different from GW4064 analogs, has been developed with FXR-450 (WAY-362450, XL335) as the leading compound (63). FXR-450 lowers plasma TG and cholesterol in different rodent models of dyslipidemia (119) and reduces atherosclerotic lesions in LDLR-deficient mice fed a high-fat diet (63). The FXR-450 analog 14cc further decreases plasma TG, VLDL, and LDL-C in normolipemic rhesus monkeys, associated with reduced CYP7A1 and increases LDLr mRNA expression (120). FXR-450 has entered phase I studies in 2007 to analyze safety, tolerability, and pharmacokinetics in healthy Japanese men (http://clinicaltrials.gov; NCT00509756) and in healthy men and women in the US (http://clinicaltrials.gov; NCT00499629), but the results have not been reported.

Altogether, accumulating proof from animal and human studies shows that FXR activation reduces hypertriglyceridemia and improves insulin resistance and NAFLD, but it has unfavorable effects on cholesterol concentrations. Further studies are necessary to assess the full potential of FXR agonists in clinical settings.

**FXR antagonists**

The only FXR antagonist so far described is guggulsterone, found in the oleoresin of the guggul tree (= guggulipid). Guggulsterone inhibits FXR activation by CDCA or GW4064 in vitro by impairing coactivator recruitment and corepressor release from the receptor (124). However, alone it is without effect on FXR activity (124, 125). In wild-type but not FXR-deficient mice fed a cholesterol-enriched diet, guggulsterone lowers hepatic cholesterol content (125), whereas it lowers plasma TG and increases HDL-C in rats (126). Curiously, guggulsterone enhances the FXR agonist-mediated induction of the BA transporter bile salt export pump (BSEP) and is thus rather a selective FXR modulator (SBARM) than a full antagonist (126). Guggulsterone further activates PXR (125), steroid and xenobiotic receptor (SXR) (124), and the progesterone receptor and binds to a variety of other receptors (127), hence lacking selectivity for FXR.

Guggulipid is traditionally used in Ayurvedic medicine, and it has been approved since 1987 in India to treat...
Structurally different ligands can bind differently to the FXR ligand binding pocket, whose intrinsic plasticity is defined by two cavities that can fit ligand substructures. Hypercholesterolemic adults (n = 61) were treated with 50 mg guggulipid twice daily for 24 weeks in addition to a fruit- and vegetable-enriched diet. The treatment decreases plasma TG as well as total and LDL-C levels, whereas HDL-C does not change (128). In a second double-blind, randomized, placebo-controlled study performed in a Western population of hyperlipidemic adults consuming a normal Western diet (n = 105), a guggu extract containing 2.5% guggulsterone was administered three times daily (1 g and 2 g per dose) for 8 weeks. No changes are observed in plasma TG, VLDL, total cholesterol, or HDL-C, but LDL-C levels increase 4–5% compared with placebo controls (129). The reasons for these contradicting results are unclear.

Selectronic bile acid receptor modulators

As mentioned above, FXR agonists of different chemical classes may activate different target gene patterns (122). Structurally different ligands can bind differently to the FXR ligand binding pocket, whose intrinsic plasticity is defined by two cavities that can fit ligand substructures (130, 131). Depending on the (stereo)chemical properties of the ligand, the exact site of binding, the closeness of the ligand-receptor conformation, and the strength of the binding can differ (122, 123, 130). The specific ligand-receptor conformation can determine the ability of coregulators to act (i.e., activators to bind or repressors to dissociate), which defines the gene selectivity of a given ligand. Those effects might also explain opposing biological “outputs” of different ligands on the same target. They further offer the possibility to develop selective bile acid receptor modulators (SBARM), which can exert a desired beneficial effect, such as the inhibition of lipogenesis to lower plasma TG, while avoiding side effects (e.g., lowering HDL-C or increasing LDL-C).

AGN34 is a selective FXR modulator, which in the intestinal cell line Caco-2 inhibits the intestinal BA binding protein (IBABP) without affecting SHP expression, both direct FXR target genes (132). In HepG2 cells, AGN34 again has no effect on SHP and decreases CYP7A1 expression, leading to the conclusion that AGN34 acts as an antagonist on IBABP expression but as an agonist on CYP7A1 expression, hence, as a gene-selective modulator (132). However, the mechanism by which AGN34 lowers CYP7A1 expression in a SHP-independent manner in isolated hepatocytes remains unknown.

TGR5 agonists

Compared with FXR, no TGR5 agonist has entered a clinical trial yet. However, TGR5 modulators are expected to be useful for the treatment of T2D, and an emerging function of TGR5 in monocytes and macrophages (133) might open up therapeutic options to target the inflammatory component of CVD and T2D.

TGR5 is activated by the same endogenous BA as FXR, although in a different order of potency (LCA > DCA > CDCA > CA) (24). CA activation of TGR5 has revealed a role for BA in the TGR5-dependent regulation of energy expenditure (96).

A naturally occurring triterpene from olive tree leaves, oleanolic acid also activates TGR5. Addition of oleanolic acid to a high-fat diet tends to reduce weight gain and improves glucose tolerance in mice (97). Oleanolic acid also attenuates colitis in a murine model, suggesting a role for TGR5 in intestinal barrier function (134). Another triterpene, betulinic acid, also exhibits TGR5-activating properties. However, derivatives of the compound with an improved potency have no effect on obesity or glucose tolerance in vivo (135).

As for FXR, a semisynthetic, steroidial derivative of CDCA has been developed that is a TGR5 agonist. INT-777 is well absorbed in vivo and undergoes enterohepatic cycling, largely without conjugation (136). The compound exerts a cholERIC effect in rats (136) with TGR5 dependency having recently been demonstrated in mice (95). INT-777 increases GLP-1 release from intestinal L-cells ex vivo (136) and in vivo, and it improves glucose tolerance (98). Similar to BA, INT-777 increases energy expenditure in mice fed a high-fat diet (98). INT-777 also inhibits atherosclerosis by exerting anti-inflammatory effects in macrophages (99). Thus, the compound today presents the most promising TGR5 agonist developed into a therapeutic for metabolic disorders.

A number of synthetic nonsteroidal compounds have been described, but they have very few in vivo analyses. Compound 32, a quinoline, shows modest bioavailability, but increases GLP-1 release and improves oral glucose tolerance in a diet-induced obesity mouse model (137). A group of isoazolecarboxamides are potent TGR5 activators, increasing GLP-1 release in dogs while reducing portal vein glucose concentrations (138). XL475, a third compound, was designed to selectively target TGR5 in the intestine without exerting systemic effects. According to the manufacturer’s website, XL475 increases GLP-1 secretion in multiple species, improves glucose tolerance, plasma, and hepatic lipid levels, and reduces hepatic steatosis in preclinical models of T2D (www.exelixis.com/pipeline/xl475). Information from patent literature further identifies a pyrimidine benzyl ester that potently activates TGR5 (139). The synthetic agonist BR27 has been reported to inhibit LPS-induced cytokine release from Kupffer cells (140), suggesting anti-inflammatory activities. Recently, ciprofloxacin has been found to activate TGR5 and reduce colitis in a mouse model (134).

Thus, TGR5 agonists might improve glucose intolerance by increasing energy expenditure and/or GLP-1 secretion, in addition to being potentially anti-inflammatory.

The semisynthetic steroidal compound INT-767 has dual agonist properties for TGR5 and FXR, being 10 times more potent for FXR than for TGR5. INT-767 decreases plasma TG and cholesterol in db/db and streptozotocin-treated mice (141). Further, it has hepatoprotective effects in a mouse model of genetic cholangiopathy, illustrated by
an improvement of plasma liver enzymes, hepatic inflammation, and biliary fibrosis (142). Curiously, such effect is not observed with the single FXR or TGR5 agonists INT-747 and INT-777 (142). Although the combined potential benefit of FXR and TGR5 activation on lipid and glucose metabolism is intriguing, the synergistic advantage of INT-767 over single FXR or TGR5 agonists, as demonstrated for cholangiopathy, still needs to be proved for metabolic disorders.

Bile acid sequestrants

BA homeostasis and, by deduction, the activity of BA receptors can be modulated by BAS, nonabsorbable resins that complex BA in the intestinal lumen and direct them toward excretion. Consequently, the BA pool is depleted by about 40% (143), which is compensated for by an increase in BA synthesis. BAS are cross-linked polymers, which interact with the hydrophobic core of the BA, and they possess cationic side-chains that bind the BA’s carboxyl group by electrophysical interaction. Binding characteristics vary for different BAS. Cholestyramine and colestipol, BAS of the first generation, preferentially bind dihydroxy (CDCA and DCA) instead of trihydroxy BA (CA), rendering the pool composition more hydrophilic (143) and probably diminishing the efficacy of BA binding to the resin due to the decreasing proportion of dihydroxy BA. Second-generation BAS, such as colesvelam, are considered to bind di- and trihydroxy BA equally well. However, BA pool composition analysis upon colesvelam treatment revealed an increased hydrophilicity due to an elevated CA synthesis and a decreased CDCA and DCA pool size, suggesting that the specificity of colesvelam might not be so different from other BAS (144). A reduced pool size of CDCA and DCA, potent endogenous FXR ligands, might be synonymous with a decreased FXR activation, making it conceivable that the effects of BAS on metabolic homeostasis are in part mediated by FXR.

Since decades, BAS are established as treatment for hypercholesterolemia. An early study showed that resin treatment of dyslipidemic patients decreases LDL-C up to 30% without affecting HDL-C (145), and a multicenter long-term trial in a large number of patients showed that the cholesterol-lowering effect of BAS is associated with a 19% decrease in the risk for CVD death and/or nonfatal myocardial infarction (146). However, BAS treatment is counterindicated when TG levels are elevated, as VLDL production may further increase upon treatment (52). Since then, a large body of evidence has confirmed the overall LDL-C-lowering and TG-increasing properties of different BAS with discordant results on HDL-C concentrations (reviewed in Ref. 38). BAS specifically reduce LDL particle number, with a preference for small LDL (147–149), which are considered especially atherogenic. Further, BAS therapy is frequently used in combination with other lipid-lowering drugs (e.g., statins, fibrates, ezetimibe, niacin) to obtain a better global risk control or in cases of drug intolerance (see Ref. 38).

Part of the LDL-C-lowering and TG-increasing effects of BAS might be mediated by FXR. Relieve of FXR-mediated inhibition of lipogenesis increases hepatic steatosis at least in rodents (150). Administration of colesteviside for 24 weeks lowers ALT and aspartate aminotransferase (AST), but not GGT in NASH patients. Unfortunately, the effect on NASH itself has not been evaluated by histological analysis of a follow-up biopsy (151). Thus, the effect of BAS on hepatic steatosis and NASH remains to be determined.

BAS also lower blood glucose in T2D patients, reducing both fasting plasma glucose and HbA1c levels (152–154). Inadequately controlled T2D patients on insulin, sulfonylurea, or metformin therapy also benefit from BAS administration in terms of glucose control (155–157). Surprisingly, the glucose-lowering effect of BAS appears not to be mediated by an improvement of insulin sensitivity as measured by hyperinsulinemic euglycemic clamps (158), glucose, or meal tolerance tests (159–161). In contrast, one week administration of colestimate in T2D patients (n = 16) lowers plasma glucose and increases postprandial GLP-1 (162). A second study evaluating glucose kinetics in T2D patients after BAS treatment finds improved glucose clearance and increased GLP-1 and gastric inhibitory peptide (GIP) concentrations (163). In diabetic rat models, BAS decrease plasma glucose and improve glucose tolerance associated with an increase in plasma GLP-1 (164, 165). Beynen et al. further observe no effect of BAS treatment on hepatic glucose production (163), similar to that reported in a diabetic mouse model (166). Thus, the contribution of FXR to the effects of BAS is unclear. Instead, it has been proposed that BAS-sequestered BA can activate TGR5 expressed in L-cells of the intestinal wall (100) or that, due to impaired micelle formation, unabsorbed long-chain fatty acids stimulate GPR40 (158), both effects promoting GLP-1 secretion.

CONCLUSION

Today, the link between BA and metabolic homeostasis is well established. Data demonstrating the contribution of BAS to the regulation of different pathways in lipid, glucose, and energy metabolism by FXR- and TGR5-mediated signaling keeps accumulating. Recent clinical studies have confirmed that the activation of FXR is beneficial for the treatment of hypertriglyceridemia but detrimental for plasma cholesterol levels, whereas deactivation of FXR by BAS lowers elevated plasma cholesterol at the expense of increasing TG. FXR activation further appears to improve insulin resistance and liver status in T2D patients. The mechanism of the glucose-lowering action of BAS remains under investigation, but it seems to be mediated by TGR5-mediated stimulation of the incretin system rather than by FXR signaling pathways.

Clearly, the modulation of FXR as well as TGR5 activity has a growing potential for the treatment of the MS. The development of selective modulators of action (SBARM) or combinatory FXR/TGR5 agents might increase the therapeutic possibilities.
REFERENCES


Bile acid receptors as therapeutic targets for dislipidemia Q1 1735


